Efficacy of silymarinum at chronic diffuse liver diseases
Abstract
The aim of review. To present modern data of foreign literature on efficacy of preparation of Silybum marianum – silymarinum at patients with alcoholinduced liver disease, non-alcoholic steatohepatosis and primary biliary cirrhosis.
Original positions. Analysis of literary data demonstrated, that silymarinum is a safe pharmaceutical and, despite of a plenty of clinical and experimental publications, its efficacy at alcoholic liver disease and primary biliary cirrhosis requires further studying as series of systematic reviews and metaanalyses are subject for discussion due to the absence of uniform methodological approaches, application of drugs with different pharmakokinetics and because of ignoring of evidencebased medicine requirements.
Conclusion. Application of the uniform silymarinum standard and carrying out of further investigations adhering to requirements of evidence-based medicine, should finally resolve present contradictions in assessment of efficacy of standardized silymarinum in patients with alcoholic liver disease, non-alcoholic steatohepatosis and primary biliary cirrhosis.
About the Authors
A. V. Matvieiev
Государственное учреждение «Крымский государственный медицинский университет им. С.И. Георгиевского Министерства здравоохранения Украины»
Ukraine
Ukraine
E. I. Konyaeva
Государственное учреждение «Крымский государственный медицинский университет им. С.И. Георгиевского Министерства здравоохранения Украины»
Ukraine
Ukraine
N. V. Matvieieva
Государственное учреждение «Крымский государственный медицинский университет им. С.И. Георгиевского Министерства здравоохранения Украины»
Ukraine
Ukraine
References
1. Матвеев А.В., Коняева Е.И., Курченко В.П., Щекатихина А.С. Гепатопротективные свойства силимарина // Эксп. клин. гастроэнтерол. – 2011. – № 2. – С. 130–136.
2. Щекатихина А.С. Гепатопротекторные свойства флаволигнанов // Труды Белорусского гос. ун-та. – 2009. – T. 4, № 1. – С. 27–48.
3. Abenavoli L., Aviello G., Capasso R. et al. Milk thistle for treatment of nonalcoholic fatty liver disease // Hepat. Mon. – 2011. – Vol. 1, N 3. – P. 173–177.
4. Angulo P., Patel T., Jorgensen R.A. et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid // Hepatology. – 2000. – Vol. 32. – P. 897–900.
5. Bergheim I., McClain C.J., Arteel G.E. Treatment of alcoholic liver disease // Dig. Dis. – 2005. – Vol. 23, N 3–4. – P. 275–284.
6. Deák G., Müzes G., Láng I. et al. Immunomodulator effect of silymarin therapy in chronic alcoholic liver digestive diseases // Orv. Hetil. – 1990. – Vol. 131, N 24. – P. 1291–1292, 1295–1296.
7. El-Awady E.S., Moustafa Y.M., Abo-Elmatty D.M. et al. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies // Eur. J. Pharmacol. – 2011. – Vol. 650, N 1. – P. 335–341.
8. Fan J.G., Jia J.D., Li Y.M. et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010 // J. Dig. Dis. – 2011. – Vol. 12, N 1. – P. 38–44.
9. Federico A., Trappoliere M., Tuccillo C. et al. A new silybin vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations // Gut. – 2006. – Vol. 55, N 6. – P. 901–902.
10. Fehér J., Deák G., Müzes G. et al. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases // Orv. Hetil. – 1989. – Vol. 130, N 51. – P. 2723–2727.
11. Ferenci P., Dragosics B., Dittrich H. et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver // J. Hepatol. – 1989. – Vol. 9, N 1. – P. 105–113.
12. Hajaghamohammadi A.A., Ziaee A., Rafiei R. The efficacy of silymarin in decreasing transaminase activities in nonalcoholic fatty liver disease: a randomized controlled clinical trial // Hepat. Mon. – 2008. – Vol. 8, N 3. – P. 191–195.
13. Hashemi S.J., Hajiani E., Sardabi E.H. A placebocontrolled trial of silymarin in patients with nonalcoholic fatty liver disease // Hepat. Mon. – 2009. – Vol. 9, N 4. – P. 265–270.
14. Held C. Fibrose-Hemmung unter Praxisbedingen // Therapiewoche. – 1992. N 42. – P. 1696–1701.
15. Held C. Therapie der toxischen Hepatopathien. Mariendistel verringert Fibroseaktivität // Therapiewoche. – 1993. – N 43. – P. 2002–2009.
16. Kumagi T., Heathcote E.J. Primary biliary cirrhosis // Orphanet J. Rare Dis. – 2008. – Vol. 3. – P. 1–17.
17. Lindor K.D., Gershwin M.E., Poupon R. et al. Primary biliary cirrhosis // Hepatology. – 2009. – Vol. 50, N 1. – P. 291–308.
18. Loguercio C., Federico A., Trappoliere M. et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study // Dig. Dis. Sci. – 2007. – Vol. 52, N 9. – P. 2387–2395.
19. Murata N., Murakami K., Ozawa Y. et al. Silymarin attenuated the amyloid β plaque burden and improved behavioral abnormalities in an Alzheimer’s disease mouse model // Biosci. Biotechnol. Biochem. – 2010. – Vol. 74, N 11. – P. 2299–2306.
20. Müzes G., Deák G., Láng I. et al. Effect of silimarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease (double blind protocol) // Orv. Hetil. – 1990. – Vol. 131, N 16. – P. 863–866.
21. O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease // Am. J. Gastroenterol. – 2010. – Vol. 105, N 1. – P. 14–32.
22. Pár A., Róth E., Rumi G.Jr. et al. Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C // Orv. Hetil. – 2000. – Vol. 141, N 30. – P. 1655–1659.
23. Pares A., Planas R., Torres M. et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial // J. Hepatol. – 1998. – Vol. 28, N 4. – P.615–621.
24. Rambaldi A., Bradly P.J., Iaquinto G. et al. Milk thistle for alcoholic and/or hepatitis B or C liver diseases – a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials // Am. J. Gastroenterol. – 2005. – Vol. 100, N 11. – P. 2583–2591.
25. Rockey D.C. Current and future anti-fibrotic therapies for chronic liver disease // Clin. Liver Dis. – 2008. – Vol. 12, N 4. – P. 939–962.
26. Saller R., Brignoli R., Melzer J., Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin // Forsch. Komplementmed. – 2008. – Vol. 15, N 1. – P. 9–20.
27. Saller R., Meier R., Brignoli R. The use of silymarin in the treatment of liver diseases // Drugs. – 2001. – Vol. 61, N 14. – P. 2035–2063.
28. Salmi H.A., Sarna S. Effects of silymarin on chemical, functional and morphological alterations of the liver. A double-blind controlled study // Scand. J. Gastroenterol. – 1982. – Vol. 17, N 4. – P. 517–521.
29. Shiha G., Sarin S.K., Ibrahim A.E. et al. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) // Hepatol. Int. – 2009. – Vol. 3, N 2. – P. 323–333.
30. Song Z., Deaciuc I., Song M. et al. Silymarin protects against acute ethanol-induced hepatotoxicity in mice // Alcohol. Clin. Exp. Res. – 2006. – Vol. 30, N 3. – P. 407–413.
31. Tilg H., Day C.P. Management strategies in alcoholic liver disease // Nat. Clin. Pract. Gastroenterol. Hepatol. – 2007. – Vol. 4, N 1. – P. 24–34.
32. Trinchet J.C., Coste T., Levy V.G. et al. Treatment of alcoholic hepatitis with silymarin. A double blind comparative study in 116 patients // Gastroenterol. Clin. Biol. – 1989. – Vol. 13, N 4. – P. 120–124.
33. Varga M., Buris L., Fodor M. Ethanol elimination in man under influence of hepatoprotective silibinin // Blutalkohol. – 1991. – Vol. 28, N 6. – P. 405–408.
34. Velussi M., Cernigoi A.M., de Monte A. et al. Longterm (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients // J. Hepatol. – 1997. – Vol. 26, N 4. – P. 871–879.
35. Vidlar A., Vostalova J., Ulrichova J. et al. The safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy – a six month placebocontrolled double-blind clinical trial // Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech Repub. – 2010. – Vol. 154, N 3. – P. 239–244.
36. Vuppalanchi R., Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management // Hepatology. – 2009. – Vol. 49, N 1. – P. 306–317.
Review
For citations:
Matvieiev A.V., Konyaeva E.I., Matvieieva N.V. Efficacy of silymarinum at chronic diffuse liver diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2011;21(5):64-69. (In Russ.)
Views:
91
Email this article 
